The appropriate comparator therapy is the therapy determined by the Federal Joint Committee (G-BA) against which the additional benefit of a medicinal product must be demonstrated in the early benefit assessment. It is based on the standard of care that would exist without the medicinal product under assessment. Its determination therefore governs which study comparisons are meaningful for the German reimbursement decision.<\/p>\n
The comparator therapy must be appropriate according to the generally recognized state of medical knowledge in the respective therapeutic area. For medicinal products, approval for the relevant indication is generally required; non-drug options must be reimbursable under statutory health insurance. Preference is given to treatments whose patient-relevant benefit has already been established and which have proven effective in practice, provided this is not precluded by guidelines or the principle of cost-effectiveness.<\/p>\n
The Medicinal Products Benefit Assessment Ordinance (AM-NutzenV) requires that actual care be taken into account. As a result, the appropriate comparator therapy can be more than a single product. Non-drug therapy, best supportive care including symptomatic or palliative measures, and watchful waiting may also be considered. For clearly defined patient groups, the determination may provide for different treatment options.<\/p>\n
The dossier must present the study results in relation to the determined comparator therapy. If only a comparison against a different control is available, the suitability of indirect comparisons or additional evidence determines whether the claim of additional benefit is sound. The choice therefore affects not merely a formal table, but the entire assessment logic for benefit and harm.<\/p>\n
Companies can seek advice from the G-BA on the documents, studies, and comparator therapy to be submitted. Such advice does not replace a later decision, but it does allow the planned evidence to be aligned with the German assessment question. If the scope of approval, treatment algorithm, or state of medical knowledge changes, the project must review whether the initial assumption regarding the comparator still holds.<\/p>\n
A comparator in a clinical trial protocol is selected by the sponsor for a specific study question. The appropriate comparator therapy, by contrast, is a regulatory determination made by the G-BA for the benefit assessment under Section 35a of the German Social Code Book V (SGB V). The two may coincide, but need not. A placebo-controlled approval program, for example, cannot provide a direct answer to the German comparator question.<\/p>\n
Likewise, the existing glossary terms “comparator” and “comparator product” do not automatically refer to the appropriate comparator therapy. They may instead denote the medicinal product actually used in a study. The appropriate comparator therapy, by contrast, encompasses the standard-of-care alternative against which the extent of an additional benefit is measured in the German reimbursement assessment.<\/p>\n
The determination can also define the scope of a subsequent indirect comparison. If no direct randomized data are available for the new medicinal product and the appropriate comparator therapy, populations, study conditions, and endpoints must be sufficiently similar for a bridge to be scientifically sound. Differences in prior treatment, prognosis, or follow-up duration can weaken the conclusion regarding an additional benefit. A statistically sophisticated method does not substitute for this clinical comparability.<\/p>\n
In the case of combination therapy, it must be clearly established whether the comparator therapy includes the concomitant treatment and which component drives the comparison. In therapy sequences too, it can be decisive whether the relevant alternative is used before, after, or together with other measures. This level of detail belongs in the study protocol, SAP, and dossier presentation, as an abbreviated description of the control can misrepresent the standard of care.<\/p>\n
The designation of the comparator therapy should therefore never be read in isolation from the population and treatment line. An alternative suitable for previously treated patients may not be appropriate for first-line use.<\/p>\n
A transparent rationale for the choice of therapy also helps keep clinical and regulatory perspectives distinct. The treatment customary in an international study is not automatically the standard of care that the G-BA considers decisive for Germany.<\/p>\n
The determination requires a link between the clinical design and the German care pathway. Where multiple subpopulations exist, inclusion criteria, prior treatments, and endpoints must be documented in such a way that results can be attributed to the appropriate comparator option. A common challenge lies in reconstructing whether the treatment sequences and dosages in the control arm meet the requirements of the subsequent assessment.<\/p>\n
Full-service CROs such as Mediconomics provide support through study concepts that consider care scenarios and relevant subpopulations at an early stage, as well as through preparation for G-BA scientific advice meetings. Biostatistics and medical writing can prepare analysis plans, indirect comparisons, and dossier modules in a way that keeps the link between study data and the determined comparator therapy clearly recognizable.<\/p>\n
Can the appropriate comparator therapy consist of several options?<\/strong><\/p>\n Yes. Depending on the indication and patient group, several treatment options or supportive measures may be part of the determination.<\/p>\n Is a control arm from the approval study automatically the appropriate comparator therapy?<\/strong><\/p>\n No. The control arm answers the study question, while the G-BA determines the comparator therapy for the German additional benefit assessment.<\/p>\n May watchful waiting serve as an appropriate comparator therapy?<\/strong><\/p>\n Yes. The ordinance expressly names watchful waiting as a possible option where it reflects the standard of care.<\/p>\n The appropriate comparator therapy is the therapy determined by the Federal Joint Committee (G-BA) against which the additional benefit of a medicinal product must be demonstrated in the early benefit assessment. It is based on the standard of care that would exist without the medicinal product under assessment. Its determination therefore governs which study comparisons […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[28],"class_list":["post-8146","glossary","type-glossary","status-publish","hentry","glossary-cat-market-access-heor"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8146\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8146"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n